Lung cancer research trials
Mercy General Hospital is participating in the following lung cancer research trials. For more information about specific trial qualifications, click on the individual trial name below.
SWOG E5597
A phase III chemoprevention trial of selenium supplementation in persons with resected stage I NSCLC
GlaxoSmithKline
An open label phase II study of weekly hycamtin and carboplatin as first line treatment of chemonaive subjects with extensive small cell lung cancer (opening date to be determined)
DO410
A randomized phase III study of tarceva or placebo following concurrent docetaxel, carboplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer
SWOG SO424
Molecular epidemiology case-series study of non-small cell lung cancer in smoking and non-smoking women and men (open for patients with non-smoking history; closed for patients with smoking history)
GENENTECH AVF3671g
A randomized, double blind, placebo-controlled phase III trial comparing bevacizumab therapy with or without erlotinib after completion of chemotherapy with bevacizumab for the first line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer
For more information, contact Rhoda Pineda, BS, CCRP Research Coordinator at (916) 453-4651
